



# MESCO PHARMACEUTICALS LIMITED

Corporate Identity No. L24111UR1986PLC015895

Corp Off: Mesco Tower, H-1, Zamrudpur Community Centre, Kailash Colony, New Delhi- 110 048  
Tel: 011 29241099, 40587083, 40587085, E-mail: mescogroup@rediffmail.com

**14<sup>th</sup> February, 2015**

**Department of Corporate Services**

BSE Ltd  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai 400 001

**Ref: Symbol: MESCO PHARMACEUTICALS LTD, Scrip Code: 500274**

**Sub: Unaudited Financial Results for the Quarter ended 31<sup>st</sup> December, 2014**

**Dear Sirs**

Pursuant to Clause 41 of Listing Agreement, please find enclosed herewith Unaudited Financial results for the quarter ended 31<sup>st</sup> December, 2014 along with Limited Review Report by Statutory Auditors.

We hope you will find the above in order.

Thanking you

Yours Faithfully

**For Mesco Pharmaceuticals Ltd**

*For Mesco Pharmaceuticals Ltd.*

**N.S. Parameswaran**  
**Additional Director**  
**DIN: 00091097**

*Director*

Encl: a/a

# N. Dhawan & Co

CHARTERED ACCOUNTANTS

411, Bhera Enclave, Paschim Vihar, Outer Ring Road, Delhi - 110 087

Call: 011-4234 2154, 93 135 10400, email: mail@ndhco.com


## Review Report to MESCO PHARMACEUTICALS LIMITED

We have reviewed the accompanying statement of Standalone unaudited financial results of **MESCO PHARMACEUTICALS LIMITED ("the Company")** for the quarter ended December 31, 2014 except for the disclosures regarding 'Public Shareholding' and Promoter and Promoter Group Shareholding' which have been traced from disclosures made by management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For N. Dhawan & Co.  
Chartered Accountants  
Firm Registration No. 007095N

  
Naresh Dhawan  
Proprietor  
M. No. 85968



Date: 14.02.2015  
Place: New Delhi



## MESCO PHARMACEUTICALS LTD

CIN : L24111UR1986PLC015895

REGD.OFFICE : Mohabewalan Industrial Area, State Bank Road, Dehradun, Uttarakhand

Tel. :011-29241099, E-mail : mescogroup@rediffmail.com

### UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED 31<sup>ST</sup> DECEMBER, 2014

Amount (in Rs.)

Sl No	PARTICULARS	Quarter Ended			Nine Month Ended		Year Ended
		31.12.2014	30.09.2014	31.12.2013	31.12.2014	31.12.2013	31.03.2014
		UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
<b>PART - I</b>							
1	<b>Income from Operations</b>						
	(a) Net Sales/ Income from operations (Net of excise duty)	0.00	0.00	0.00	0.00	0.00	0.00
	(b) Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
	<b>Total Income from Operations (net)</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
2	<b>Expenses</b>						
	(a) Cost of Material Consumed	0.00	0.00	0.00	0.00	0.00	0.00
	(b) Purchases of Traded goods	0.00	0.00	0.00	0.00	0.00	0.00
	(c) Change in Inventories of finished goods and work in progress	0.00	0.00	0.00	0.00	0.00	0.00
	(d) Employees Benefits Expenses	0.00	0.00	0.00	0.00	0.00	0.00
	(e) Depreciation and Amortisation expenses	117737159.00	117737159.00	0.00	353211477.00	0.00	0.00
	(f) Other Expenses	3025.00	625.00	2545.00	4275.00	5545.00	19045.00
	<b>Total Expenses</b>	<b>117740184.00</b>	<b>117737784.00</b>	<b>2545.00</b>	<b>353215752.00</b>	<b>5545.00</b>	<b>19045.00</b>
3	<b>Profit/(Loss) from Operations before other Income, Finance Costs &amp; Exceptional Items (1-2)</b>	<b>(117,740,184.00)</b>	<b>(117,737,784.00)</b>	<b>(2,545.00)</b>	<b>(353,215,752.00)</b>	<b>(5,545.00)</b>	<b>(19,045.00)</b>
4	Other Income	0.00	0.00	0.00	0.00	0.00	327779.44
5	<b>Profit/(Loss) from Ordinary activities before finance costs and Exceptional Items (3+4)</b>	<b>(117,740,184.00)</b>	<b>(117,737,784.00)</b>	<b>(2,545.00)</b>	<b>(353,215,752.00)</b>	<b>(5,545.00)</b>	<b>308734.44</b>
6	Finance Costs	0.00	102.00	0.00	2052838.00	328585.00	328585.00
7	<b>Profit/(Loss) from ordinary activities after finance costs but before Exceptional Items (5-6)</b>	<b>(117,740,184.00)</b>	<b>(117,737,886.00)</b>	<b>(2,545.00)</b>	<b>(355,268,590.00)</b>	<b>(334,130.00)</b>	<b>(19,850.56)</b>
8	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
9	<b>Profit/(Loss) from Ordinary Activities before Tax (7-8)</b>	<b>(117,740,184.00)</b>	<b>(117,737,886.00)</b>	<b>(2,545.00)</b>	<b>(355,268,590.00)</b>	<b>(334,130.00)</b>	<b>(19,850.56)</b>
10	Tax Expenses	0.00	0.00	0.00	0.00	0.00	0.00
11	<b>Net Profit/(Loss) from Ordinary Activities after Tax (9-10)</b>	<b>(117,740,184.00)</b>	<b>(117,737,886.00)</b>	<b>(2,545.00)</b>	<b>(355,268,590.00)</b>	<b>(334,130.00)</b>	<b>(19,850.56)</b>
12	Extraordinary Items (net of tax expense)	0.00	0.00	0.00	0.00	0.00	0.00
13	<b>Net Profit/(Loss) for the period (11-12)</b>	<b>(117,740,184.00)</b>	<b>(117,737,886.00)</b>	<b>(2,545.00)</b>	<b>(355,268,590.00)</b>	<b>(334,130.00)</b>	<b>(19,850.56)</b>
14	Paid up Equity Share Capital (Face value Rs.10/- per Equity Share)	197381000.00	197381000.00	197381000.00	197381000.00	197381000.00	197381000.00
15	Reserves & Surplus (Excluding Revaluation Reserves) (as per audited balance sheet of as at 31st March 2014)	162189032.00	162189032.00	162189032.00	162189032.00	162189032.00	162189032.00
16 (i)	<b>Earning per share (Rs.)</b>						
	<b>Basic &amp; Diluted EPS</b>						
	-Before Extra Ordinary Items	(5.79)	(5.79)	(0.00)	(17.48)	(0.02)	(0.00)
	-After Extra Ordinary Items	(5.79)	(5.79)	(0.00)	(17.48)	(0.02)	(0.00)
<b>PART II: Select information for the Quarter Ended December 31,2014</b>							
A	<b>PARTICULARS OF SHAREHOLDING</b>						
1	<b>Public Shareholding</b>						
	-Number of Shares	12334500	12334500	12334500	12334500	12334500	12334500
	- Percentage of Shareholding	60.70%	60.70%	60.70%	60.70%	60.70%	60.70%
2	<b>Promoters and Promoter group shareholding</b>						
	<b>a) Pledged/ Encumbered</b>						
	i) Number of Shares	0.00	0.00	0.00	0.00	0.00	0.00
	ii)% of Shareholding (as a % of the total share holding of promoters and promoter group)	0.00	0.00	0.00	0.00	0.00	0.00
	iii) % of Shareholding (as a % of the total share capital of the company)	0.00	0.00	0.00	0.00	0.00	0.00
	<b>b) Non-Encumbered</b>						
	i) Number of Shares	7986100	7986100	7986100	7986100	7986100	7986100
	ii)% of Shareholding (as a % of the total share holding of promoters and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
	iii) % of Shareholding (as a % of the total share capital of the company)	39.30%	39.30%	39.30%	39.30%	39.30%	39.30%
B	<b>INVESTOR COMPLAINTS</b>						
	Pending at the beginning of the quarter	: NIL					
	Disposed of during the quarter	: 1					

**Notes :**

- The above Financial Results were reviewed by the Audit Committee and approved by the Board of Directors in its Meeting held on 14th February, 2015.
- Figures for the previous period have been regrouped/rearranged/reclassified wherever necessary.
- The Limited Review as required under clause 41 of the Listing Agreement has been completed by the Statutory Auditors.

FOR AND ON BEHALF OF THE BOARD  
MESCO PHARMACEUTICALS LTD

N.S. Parmeswaran

Additional Director

DIN : 00091097

PLACE New Delhi  
DATED : 14.02.2015

*Mesco Pharmaceuticals Ltd.*

Director